Last edited by Shakatilar
Sunday, July 12, 2020 | History

4 edition of Antifolate drugs in cancer therapy found in the catalog.

Antifolate drugs in cancer therapy

Antifolate drugs in cancer therapy

  • 108 Want to read
  • 15 Currently reading

Published by Humana Press in Totowa, N.J .
Written in English

    Subjects:
  • Folic acid -- Antagonists -- Therapeutic use.,
  • Cancer -- Chemotherapy.,
  • Antimetabolites -- Therapeutic use.,
  • Folic acid -- Derivatives -- Therapeutic use.

  • Edition Notes

    Includes bibliographical references and index.

    Statementedited by Ann L. Jackman.
    SeriesCancer drug discovery and development
    ContributionsJackman, Ann L.
    Classifications
    LC ClassificationsRC271.F6 A58 1999
    The Physical Object
    Paginationx, 456 p. :
    Number of Pages456
    ID Numbers
    Open LibraryOL20001659M
    ISBN 100896035964
    LC Control Number00501973

    Targeted Drug Strategies for Cancer and Inflammation: Medicine & Health Science Books @   Pemetrexed (ALIMTA, LY, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including Cited by:

    antifolate chemotherapy: Antifolate therapy Oncology The use of an antimetabolite–eg, MTX, to compete with folate, inhibiting dihydrofolate reductase, the enzyme responsible for → inactive dihydrofolate into an active tetrahydrofolate; this block causes a buildup of toxic dihydrofolate, shutting down synthesis of purine nucleotides and.   (see, generally, Antifolate Drugs in Cancer Therapy, edited by Jackman, Ann L., Humana Press, Totowa, N.J., ) In some cases, a supportive intervention is routinely used to permit safe, maximal dosing. For example, steroids, such as dexamethone, can be used to prevent the formation of skin rashes caused by the antifolate. (Antifolate, pg ).

    The expense of developing cancer drugs, and their cost to patients and insurers, would clearly be worth it if the drugs promised cures or even deep remissions, but the vast majority of new drugs.   Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as an important target for cancer therapy. Experimental Design: We evaluated FRα expression in breast cancers by genomic (n = 3,) and Cited by: 7.


Share this book
You might also like
Plan It

Plan It

Journal of Mule Train Packing in Eastern Washington in the 1860s

Journal of Mule Train Packing in Eastern Washington in the 1860s

Solving management problems in information services

Solving management problems in information services

Neurotic Styles

Neurotic Styles

Washington forest productivity study

Washington forest productivity study

The Theater of Refusal

The Theater of Refusal

walk around Alcester, Warwickshire

walk around Alcester, Warwickshire

Surprise Present

Surprise Present

A bag full of pups

A bag full of pups

Studies in comparative theology

Studies in comparative theology

Life of a River

Life of a River

Advanced-fueled fusion reactors suitable for direct energy conversion

Advanced-fueled fusion reactors suitable for direct energy conversion

Prehistoric sea monsters

Prehistoric sea monsters

Methodology in sex research

Methodology in sex research

Surgery of the dog and cat

Surgery of the dog and cat

History, morality and public order

History, morality and public order

creed

creed

Antifolate drugs in cancer therapy Download PDF EPUB FB2

In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs.

The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors, Author: Ann L. Jackman. In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs.

The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors. Antifolate drugs, such as the dihydrofolate reductase (DHFR) inhibitor methotrexate (MTX), have been used in the treatment of cancer for more than 50 years.

Increased understanding of the biochemistry of folate-dependent pathways, folate transporters, drug resistance, and downstream effects of target inhibition has led to the discovery of new. In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs.

The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors,Brand: Humana Press. Antifolate Drugs in Cancer Therapy by Ann L.

Jackman,available at Book Depository with free delivery worldwide. In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs.

The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate. Recent years have seen two new antifolate drugs approved for marketing: trimetrexate (Neutrexin), a lipophilic inhibitor of dihydrofolate reductase (DHFR) for treatment of the life-threatening fungal infection, Pneumocystis carinii pneumonia; and the thymidylate synthase (TS) inhibitor, raltitrexed (Tomudex), for colorectal cancer.

In addition. The NCI Dictionary of Cancer Terms features 8, terms related to cancer and medicine. We offer a widget that you can add to your website to let users look up cancer-related terms. Get NCI’s Dictionary of Cancer Terms Widget. Antifolate Drugs: Past and Future Perspectives, Robert C.

Jackson. Folate Biochemistry and Nutrition in Relation to Antifolate Selectivity, Roy L. Kisliuk. Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors, Richard Gorlick and Joseph R. Bertino. While renewing tissues of the bone marrow and intestinal tract are also folate-dependent and are sites of antifolate toxicity, the clinical utility of antifolates was established with the identification of doses and schedules of administration that provided sufficient selectivity to make these drugs effective in the treatment of cancer as well.

Get this from a library. Antifolate drugs in cancer therapy. [Ann L Jackman;] -- In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs.

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for lung cancer. The list includes generic and brand names. This page also lists common drug combinations used in lung cancer.

The individual drugs in the combinations are FDA-approved. However, the drug combinations themselves usually are not approved, although. PDF | 5 Fluorouracil (5FU) is a rationally designed antineoplastic agent (1,2) with distinct antifolate and antipyrimidine properties.

5FU is usually | Find, read and cite all the research you. Book reviews Book reviews, Eur J Clin Pharmacol () ± Ó Springer-Verlag Antifolate drugs in cancer therapy Ann L Jackman (ed) ; deserves a place on the shelf of any clinician or scientist involved in pp; hardcover £ ISBN Humana Press, the research or management of cancer.

The latter cells lack the capacity to synthesize folates. In some patients, high dosages of antifolate drugs (eg: methotrexate, pemetrexed) used in cancer chemotherapy alter the keratinocytes, endothelial cells and Factor XIIIa+ dermal dendrocytes in a range of various by: 4.

Pemetrexed disodium (ALIMTA ®, “pemetrexed”) is a novel, multi‐targeted antifolate that has demonstrated promising clinical activity in a wide variety of solid tumors, including non‐small cell lung, breast, mesothelioma, colorectal, pancreatic, gastric, bladder, cervix, and head and exed inhibits multiple folate‐dependent enzymes involved in both purine and pyrimidine Cited by: Request PDF | On Jan 1,Yongyuth Yuthavong and others published Antifolate Drugs | Find, read and cite all the research you need on ResearchGate.

Anticancer therapy is constantly changing; it has entered the postgenomic era, enabling a development of drugs that target cancer cells and do not harm the healthy cells.

Specific targets in cancer cells available for potential treatment are presented, with a brief description how these targets can be identified, validated, and used in clinical.

Free 2-day shipping. Buy Cancer Drug Discovery & Development: Antifolate Drugs in Cancer Therapy (Hardcover) at nd: Ann L Jackman. Book 8 -ANTINEOPLASTIC DRUGS Third Edition Prepared by Evelyn M. Shambaugh, M.A., CTR children with acute lymphoblastic leukemia led to the development of antifolate agents in the early 's.

This new approach to cancer therapy made it possible to File Size: 6MB. Pemetrexed is a newly approved antifolate agent for the treatment of malignant pleural mesothelioma (MPM) and metastatic non-small cell lung cancer (NSCLC). We performed a PubMed/MEDLINE database search to identify relevant literature from January April Folate pathways are essential in metabolism and macromolecule synthesis.

Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the.Access: Online book.

2. Radioimmunoassay in Basic and Clinical Pharmacology. Published: Access: Online book. 3. Handbook of psychiatric drug therapy. Antifolate Drugs in Cancer Therapy. By: Jackman, Ann L Published: Access: Online book.